| Virksomhedsstatus | | NORMAL. |
| Sidst opdateret den 21.03.2018 og
angivet som gældende fra 20.03.2018 (2237
dage). |
Ingen historik.
| Branche | | Fremstilling af farmaceutiske præparater (212000). |
| Sidst opdateret den 21.03.2018 og
angivet som gældende fra 20.03.2018 (2237
dage). |
Ingen historik.
| Revisionfravalgt | | false. |
| Sidst opdateret den 08.04.2020 og
angivet som gældende fra 08.04.2020 (1487
dage). |
| Historik | Start | Stop |
|---|
| false | 08.04.2020 | |
| true | 20.03.2018 | 07.04.2020 |
| Kontaktoplysninger | | INFO@DANCANN.COM. |
| Sidst opdateret den 23.08.2021 og
angivet som gældende fra 23.08.2021 (985
dage). |
| Historik | Start | Stop |
|---|
| INFO@DANCANN.COM | 23.08.2021 | |
| JKR@DANCANN.COM | 30.04.2018 | 22.08.2021 |
| Telefonnummer | | 69160393. |
| Sidst opdateret den 23.08.2021 og
angivet som gældende fra 23.08.2021 (985
dage). |
| Historik | Start | Stop |
|---|
| 69160393 | 23.08.2021 | |
| 29636920 | 30.04.2018 | 22.08.2021 |
| Navne | | DANCANN PHARMA A/S. |
| Sidst opdateret den 04.08.2020 og
angivet som gældende fra 06.07.2020 (1398
dage). |
| Historik | Start | Stop |
|---|
| DANCANN PHARMA A/S | 06.07.2020 | |
| DANCANN PHARMA ApS | 26.06.2020 | 05.07.2020 |
| DANCANN PHARMA IVS | 04.12.2019 | 25.06.2020 |
| DANCANN IVS | 20.03.2018 | 03.12.2019 |
| Binavne | | Danish Cannabinoids Pharmaceuticals A/S. |
| Sidst opdateret den 04.08.2020 og
angivet som gældende fra 06.07.2020 (1398
dage). |
| Historik | Start | Stop |
|---|
| Danish Cannabinoids Pharmaceuticals A/S | 06.07.2020 | |
| Danish Cannabis Pharmaceuticals A/S | 06.07.2020 | |
| Danish Cannabinoids Pharmaceuticals ApS | 26.06.2020 | 05.07.2020 |
| Danish Cannabis Pharmaceuticals ApS | 26.06.2020 | 05.07.2020 |
| Danish Cannabinoids Pharmaceuticals IVS | 04.12.2019 | 25.06.2020 |
| Danish Cannabis Pharmaceuticals IVS | 04.12.2019 | 25.06.2020 |
| Tegningsregel | | Selskabet tegnes af direktøren og bestyrelsesformanden i forening eller af den samlede bestyrelse. |
| Sidst opdateret den 08.04.2020 og
angivet som gældende fra 08.04.2020 (1487
dage). |
| Fortolkning
(2 tegningsmuligheder)
| | direktøren + formanden |
| bestyrelsen |
| Historik | Start | Stop |
|---|
| Selskabet tegnes af direktøren og bestyrelsesformanden i forening eller af den samlede bestyrelse | 08.04.2020 | |
| Selskabet tegnes af en direktør alene | 20.03.2018 | 07.04.2020 |
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:Deloitte Statsautoriseret Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:33963556
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse C, mellemstor virksomhed
Grundlag for konklusion (revision):Basis for opinionWe conducted our audit in accordance with InternationalStandards on Auditing (ISAs) and additional requirementsapplicable in Denmark. Our responsibilities under those stan-dards and requirements are further described in the “Auditor’sresponsibilities for the audit of the consolidated financialstatements and the parent financial statements” sectionof this auditor’s report. We are independent of the Group inaccordance with the International Ethics Standards Boardfor Accountants’ International Code of Ethics for Profes-sional Accountants (IESBA Code) and the additional ethicalrequirements applicable in Denmark, and we have fulfilledour other ethical responsibilities in accordance with theserequirements and the IESBA Code. We believe that the auditevidence we have obtained is sufficient and appropriate toprovide a basis for our opinion.
Konklusion (revision):OpinionWe have audited the consolidated financial statements andthe parent financial statements of Dancann Pharma A/S forthe financial year 01. 01. 2022-31. 12. 2022, which comprise theincome statement, balance sheet, statement of changes inequity and notes, including a summary of significant ac-counting policies, for the Group as well as the Parent, and theconsolidated cash flow statement. The consolidated financialstatements and the parent financial statements are preparedin accordance with the Danish Financial Statements Act. In our opinion, the consolidated financial statements and theparent financial statements give a true and fair view of theGroup’s and the Parent’s financial position at 31. 12. 2022 andof the results of their operations and the consolidated cashflows for the financial year 01. 01. 2022-31. 12. 2022 in accor-dance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Statement on the management commentaryManagement is responsible for the management commen-taryOur opinion on the consolidated financial statements and theparent financial statements døs not cover the managementcommentary, and we do not express any form of assuranceconclusion thereon. In connection with our audit of the consolidated financialstatements and the parent financial statements, our re-sponsibility is to read the management commentary and, indoing so, consider whether the management commentary ismaterially inconsistent with the consolidated financial state-ments and the parent financial statements or our knowledgeobtained in the audit or otherwise appears to be materiallymisstated. Moreover, it is our responsibility to consider whether themanagement commentary provides the information requiredunder the Danish Financial Statements Act. Based on the work we have performed, we conclude thatthe management commentary is in accordance with theconsolidated financial statements and the parent financialstatements and has been prepared in accordance with therequirements of the Danish Financial Statements Act. We didnot identify any material misstatement of the managementcommentary.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
| Hjemmeside | | https://dancann.com. |
| Sidst opdateret den 30.04.2018 og
angivet som gældende fra 30.04.2018 (2196
dage). |
Ingen historik.
LoginOpret gratis brugere-conomic integration